|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STMN1 |
Gene summary for STMN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STMN1 | Gene ID | 3925 |
| Gene name | stathmin 1 | |
| Gene Alias | C1orf215 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A0A140VJW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3925 | STMN1 | GSM4909281 | Human | Breast | IDC | 2.82e-60 | 1.05e+00 | 0.21 |
| 3925 | STMN1 | GSM4909282 | Human | Breast | IDC | 3.22e-88 | 1.24e+00 | -0.0288 |
| 3925 | STMN1 | GSM4909285 | Human | Breast | IDC | 1.09e-47 | 8.62e-01 | 0.21 |
| 3925 | STMN1 | GSM4909286 | Human | Breast | IDC | 8.42e-54 | 8.73e-01 | 0.1081 |
| 3925 | STMN1 | GSM4909287 | Human | Breast | IDC | 4.37e-30 | 8.35e-01 | 0.2057 |
| 3925 | STMN1 | GSM4909288 | Human | Breast | IDC | 2.75e-06 | 5.97e-01 | 0.0988 |
| 3925 | STMN1 | GSM4909293 | Human | Breast | IDC | 1.52e-22 | 6.59e-01 | 0.1581 |
| 3925 | STMN1 | GSM4909295 | Human | Breast | IDC | 1.36e-09 | 6.52e-01 | 0.0898 |
| 3925 | STMN1 | GSM4909296 | Human | Breast | IDC | 3.07e-09 | 2.08e-01 | 0.1524 |
| 3925 | STMN1 | GSM4909297 | Human | Breast | IDC | 1.08e-06 | 8.78e-02 | 0.1517 |
| 3925 | STMN1 | GSM4909304 | Human | Breast | IDC | 4.82e-02 | 2.48e-01 | 0.1636 |
| 3925 | STMN1 | GSM4909311 | Human | Breast | IDC | 1.21e-17 | -3.56e-01 | 0.1534 |
| 3925 | STMN1 | GSM4909312 | Human | Breast | IDC | 5.87e-07 | -9.27e-03 | 0.1552 |
| 3925 | STMN1 | GSM4909313 | Human | Breast | IDC | 1.84e-02 | -2.46e-01 | 0.0391 |
| 3925 | STMN1 | GSM4909315 | Human | Breast | IDC | 1.54e-10 | 5.55e-01 | 0.21 |
| 3925 | STMN1 | GSM4909316 | Human | Breast | IDC | 1.80e-04 | 4.09e-01 | 0.21 |
| 3925 | STMN1 | GSM4909318 | Human | Breast | IDC | 2.56e-06 | 7.50e-01 | 0.2031 |
| 3925 | STMN1 | GSM4909319 | Human | Breast | IDC | 2.00e-24 | 1.86e-02 | 0.1563 |
| 3925 | STMN1 | GSM4909321 | Human | Breast | IDC | 3.31e-08 | -2.81e-02 | 0.1559 |
| 3925 | STMN1 | M2 | Human | Breast | IDC | 4.41e-21 | 1.05e+00 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003297030 | Thyroid | HT | regulation of actin filament-based process | 49/1272 | 397/18723 | 3.65e-05 | 7.57e-04 | 49 |
| GO:190290330 | Thyroid | HT | regulation of supramolecular fiber organization | 47/1272 | 383/18723 | 6.02e-05 | 1.13e-03 | 47 |
| GO:003133327 | Thyroid | HT | negative regulation of protein-containing complex assembly | 23/1272 | 141/18723 | 7.64e-05 | 1.37e-03 | 23 |
| GO:004325430 | Thyroid | HT | regulation of protein-containing complex assembly | 50/1272 | 428/18723 | 1.24e-04 | 2.00e-03 | 50 |
| GO:003295630 | Thyroid | HT | regulation of actin cytoskeleton organization | 43/1272 | 358/18723 | 1.97e-04 | 2.87e-03 | 43 |
| GO:000701530 | Thyroid | HT | actin filament organization | 50/1272 | 442/18723 | 2.71e-04 | 3.73e-03 | 50 |
| GO:005101730 | Thyroid | HT | actin filament bundle assembly | 23/1272 | 157/18723 | 3.91e-04 | 4.90e-03 | 23 |
| GO:006157230 | Thyroid | HT | actin filament bundle organization | 23/1272 | 161/18723 | 5.63e-04 | 6.62e-03 | 23 |
| GO:006156418 | Thyroid | HT | axon development | 50/1272 | 467/18723 | 9.50e-04 | 9.83e-03 | 50 |
| GO:001063925 | Thyroid | HT | negative regulation of organelle organization | 39/1272 | 348/18723 | 1.45e-03 | 1.36e-02 | 39 |
| GO:002241123 | Thyroid | HT | cellular component disassembly | 47/1272 | 443/18723 | 1.60e-03 | 1.48e-02 | 47 |
| GO:005125828 | Thyroid | HT | protein polymerization | 34/1272 | 297/18723 | 1.99e-03 | 1.77e-02 | 34 |
| GO:190290420 | Thyroid | HT | negative regulation of supramolecular fiber organization | 22/1272 | 167/18723 | 2.14e-03 | 1.87e-02 | 22 |
| GO:003298419 | Thyroid | HT | protein-containing complex disassembly | 27/1272 | 224/18723 | 2.69e-03 | 2.24e-02 | 27 |
| GO:003111310 | Thyroid | HT | regulation of microtubule polymerization | 10/1272 | 55/18723 | 3.57e-03 | 2.73e-02 | 10 |
| GO:003103225 | Thyroid | HT | actomyosin structure organization | 24/1272 | 196/18723 | 3.67e-03 | 2.75e-02 | 24 |
| GO:005087826 | Thyroid | HT | regulation of body fluid levels | 40/1272 | 379/18723 | 3.75e-03 | 2.81e-02 | 40 |
| GO:003227128 | Thyroid | HT | regulation of protein polymerization | 27/1272 | 233/18723 | 4.64e-03 | 3.28e-02 | 27 |
| GO:003223127 | Thyroid | HT | regulation of actin filament bundle assembly | 15/1272 | 105/18723 | 4.83e-03 | 3.31e-02 | 15 |
| GO:007050710 | Thyroid | HT | regulation of microtubule cytoskeleton organization | 19/1272 | 148/18723 | 5.50e-03 | 3.62e-02 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STMN1 | SNV | Missense_Mutation | c.92N>A | p.Ser31Tyr | p.S31Y | P16949 | protein_coding | tolerated(0.06) | possibly_damaging(0.689) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| STMN1 | SNV | Missense_Mutation | novel | c.335N>A | p.Arg112Gln | p.R112Q | P16949 | protein_coding | deleterious(0.03) | possibly_damaging(0.641) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| STMN1 | SNV | Missense_Mutation | novel | c.442C>T | p.Leu148Phe | p.L148F | P16949 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| STMN1 | SNV | Missense_Mutation | c.248N>C | p.Leu83Pro | p.L83P | P16949 | protein_coding | deleterious(0.01) | possibly_damaging(0.884) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| STMN1 | SNV | Missense_Mutation | novel | c.196N>A | p.Ala66Thr | p.A66T | P16949 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-D1-A179-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
| STMN1 | SNV | Missense_Mutation | novel | c.382N>C | p.Tyr128His | p.Y128H | P16949 | protein_coding | tolerated_low_confidence(0.4) | benign(0.102) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| STMN1 | SNV | Missense_Mutation | novel | c.442N>A | p.Leu148Ile | p.L148I | P16949 | protein_coding | tolerated_low_confidence(0.32) | benign(0.015) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STMN1 | SNV | Missense_Mutation | novel | c.508C>A | p.Leu170Ile | p.L170I | P16949 | protein_coding | tolerated_low_confidence(0.16) | benign(0.408) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| STMN1 | SNV | Missense_Mutation | novel | c.86A>T | p.Lys29Ile | p.K29I | P16949 | protein_coding | tolerated(0.26) | benign(0.195) | TCGA-DD-AADS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| STMN1 | SNV | Missense_Mutation | rs763117641 | c.182G>A | p.Arg61His | p.R61H | P16949 | protein_coding | deleterious(0.03) | probably_damaging(0.935) | TCGA-BR-4256-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3925 | STMN1 | DRUG RESISTANCE | PACLITAXEL | PACLITAXEL | 24587245 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |